Hanne Capital
Overview
Hanne Capital is a venture capital firm founded in 2017. It specializes in investing in the biotech, pharma, and medtech sectors, with a focus on growth opportunities in Greater China. The firm primarily invests in Series A rounds in China-based startups across Life Sciences, High Tech, and Healthcare.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Reistone Biopharma | May 2022 | Series A | Co-investor |
| Rezubio Pharmaceuticals Co., Ltd. | Sep 2019 | Angel | Co-investor |
| Kyinno Bio | Apr 2021 | Series A | Co-investor |
| BioNova Pharmaceuticals (Shanghai) Ltd. | Nov 2020 | Series B Extension | Co-investor |
| HiFiBiO Therapeutics | Aug 2019 | Series C | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Hanne Capital based?
Hanne Capital is headquartered in Shanghai, Shanghai, China.
When was Hanne Capital founded?
Hanne Capital was founded in 2017.
How many portfolio companies does Hanne Capital have?
Hanne Capital has 5 portfolio companies in Caplight's dataset.
What are some companies in Hanne Capital's portfolio?
Portfolio companies visible on Caplight include Reistone Biopharma, Rezubio Pharmaceuticals Co., Ltd., Kyinno Bio, BioNova Pharmaceuticals (Shanghai) Ltd., HiFiBiO Therapeutics.
What was Hanne Capital's most recent investment shown here?
Hanne Capital's most recent investment in this portfolio sample was in Reistone Biopharma in 2022.
What sectors does Hanne Capital focus on?
Hanne Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Hanne Capital focus on?
Hanne Capital typically invests at the Early stage.
What is Hanne Capital's AUM?
Hanne Capital's assets under management are estimated between $100.0M and $250.0M.